MCID: PLY048
MIFTS: 19

Polycystic Kidney Disease 1, Autosomal Dominant

Categories: Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Polycystic Kidney Disease 1, Autosomal Dominant

MalaCards integrated aliases for Polycystic Kidney Disease 1, Autosomal Dominant:

Name: Polycystic Kidney Disease 1, Autosomal Dominant 24
Pkd 1 24

Classifications:



Summaries for Polycystic Kidney Disease 1, Autosomal Dominant

MalaCards based summary : Polycystic Kidney Disease 1, Autosomal Dominant, also known as pkd 1, is related to inhibited male orgasm and 48, xxxx. An important gene associated with Polycystic Kidney Disease 1, Autosomal Dominant is PKD1 (Polycystin 1, Transient Receptor Potential Channel Interacting). The drugs Curcumin and Peripheral Nervous System Agents have been mentioned in the context of this disorder. Affiliated tissues include kidney and liver.

Related Diseases for Polycystic Kidney Disease 1, Autosomal Dominant

Diseases in the Polycystic Kidney Disease family:

Polycystic Kidney Disease 5 Polycystic Kidney Disease 2
Polycystic Kidney Disease 3 Polycystic Kidney Disease 1
Autosomal Dominant Polycystic Kidney Disease Polycystic Kidney Disease 1, Autosomal Dominant
Polycystic Kidney Disease 2, Autosomal Dominant

Diseases related to Polycystic Kidney Disease 1, Autosomal Dominant via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 inhibited male orgasm 10.1 PKD1 PKD1P1
2 48, xxxx 9.8 PKD1 PKD1P1
3 charcot-marie-tooth disease, type 1c 6.7 PKD1 PKD1P1 PKD1P2 PKD1P3 PKD1P4 PKD1P5
4 primary autosomal recessive microcephaly type 2 6.6 PKD1 PKD1P1 PKD1P2 PKD1P3 PKD1P4 PKD1P5

Symptoms & Phenotypes for Polycystic Kidney Disease 1, Autosomal Dominant

Drugs & Therapeutics for Polycystic Kidney Disease 1, Autosomal Dominant

Drugs for Polycystic Kidney Disease 1, Autosomal Dominant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Investigational Phase 4 458-37-7 969516
2 Peripheral Nervous System Agents Phase 4,Phase 2
3 Analgesics Phase 4
4 Analgesics, Non-Narcotic Phase 4
5 Anti-Inflammatory Agents Phase 4
6 Anti-Inflammatory Agents, Non-Steroidal Phase 4
7 Antirheumatic Agents Phase 4
8
Pravastatin Approved Phase 3 81093-37-0 54687
9
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
10
Somatostatin Approved Phase 3 38916-34-6, 51110-01-1 53481605
11
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
12
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
13
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
14
Clonidine Approved Phase 3 4205-90-7 2803
15
Diltiazem Approved Phase 3 42399-41-7 39186
16
Hydralazine Approved Phase 3 86-54-4 3637
17
Hydrochlorothiazide Approved, Vet_approved Phase 3 58-93-5 3639
18
Lisinopril Approved, Investigational Phase 3 83915-83-7, 76547-98-3 5362119
19
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
20
Minoxidil Approved Phase 3 38304-91-5 4201
21
Telmisartan Approved, Investigational Phase 3 144701-48-4 65999
22
Tolvaptan Approved Phase 3,Phase 2 150683-30-0 216237
23 lanreotide Approved Phase 3 108736-35-2
24 Triptolide Investigational Phase 3 38748-32-2
25
Angiotensin II Investigational Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
26
Lactitol Investigational Phase 3 585-86-4 3871
27 Alkylating Agents Phase 3
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1
31 Contraceptive Agents Phase 3
32 Contraceptive Agents, Male Phase 3
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
34 Angiotensin Receptor Antagonists Phase 3,Phase 2
35 Angiotensin-Converting Enzyme Inhibitors Phase 3,Phase 2
36 Angiotensinogen Phase 3,Phase 2
37 Antihypertensive Agents Phase 3,Phase 2
38 HIV Protease Inhibitors Phase 3,Phase 2
39
protease inhibitors Phase 3,Phase 2
40 Arginine Vasopressin Phase 2, Phase 3
41 Coagulants Phase 2, Phase 3
42 Hemostatics Phase 2, Phase 3
43 Natriuretic Agents Phase 2, Phase 3
44 Vasoconstrictor Agents Phase 2, Phase 3
45 Vasopressins Phase 2, Phase 3
46 Anticholesteremic Agents Phase 3
47 Antimetabolites Phase 3,Phase 2
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
49 Hypolipidemic Agents Phase 3,Phase 2
50 Lipid Regulating Agents Phase 3,Phase 2

Interventional clinical trials:

(show all 43)

id Name Status NCT ID Phase Drugs
1 Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD Recruiting NCT02494141 Phase 4 Curcumin
2 Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Unknown status NCT02115659 Phase 3 Triptolide-Containing Formulation;Placebo
3 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease Completed NCT02225860 Phase 2, Phase 3
4 Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00456365 Phase 3 pravastatin;Placebo
5 Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study Completed NCT00309283 Phase 3 Long-acting somatostatin
6 Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00346918 Phase 3 Sirolimus
7 HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A Completed NCT00283686 Phase 3 Lisinopril;Telmisartan;Placebo
8 HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B Completed NCT01885559 Phase 3 Lisinopril;Telmisartan;Placebo
9 Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02055079 Phase 3 Sirolimus;Placebo
10 Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) Recruiting NCT02964273 Phase 3 Tolvaptan;Matching Placebo
11 The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients Recruiting NCT02134899 Phase 3 Everolimus;Calcineurin inhibitors maintenance
12 Lanreotide In Polycystic Kidney Disease Study Recruiting NCT02127437 Phase 3 Lanreotide;saline
13 Study of Lanreotide to Treat Polycystic Kidney Disease Active, not recruiting NCT01616927 Phase 3 Lanreotide
14 Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy Terminated NCT00920309 Phase 2, Phase 3 Rapamycin
15 Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control Unknown status NCT01932450 Phase 2 antihypertensive drugs
16 Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00286156 Phase 1, Phase 2 Rapamune
17 Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety Completed NCT00491517 Phase 2 Sirolimus;conventional therapy
18 Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease Completed NCT02140814 Phase 2
19 Effect of the Aquaretic Tolvaptan on Nitric Oxide System Completed NCT02527863 Phase 2 Tolvaptan;Placebo
20 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] Completed NCT00841568 Phase 2 OPC-41061
21 Bosutinib For Autosomal Dominant Polycystic Kidney Disease Completed NCT01233869 Phase 2 Bosutinib;Bosutinib;Placebo
22 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT01451827 Phase 2 Tolvaptan MR;Tolvaptan IR;Placebo
23 Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease Completed NCT02021110 Phase 2 Ursodeoxycholic Acid
24 Feasibility Study of Metformin Therapy in ADPKD Recruiting NCT02903511 Phase 2 Metformin;Placebo
25 A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Active, not recruiting NCT01559363 Phase 1, Phase 2 KD019 (tesevatinib)
26 Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease Completed NCT02166489 Phase 1
27 Clinical Implications of DNA Analysis on ADPKD Completed NCT02322385
28 Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00759369
29 ADPKD Cohort Study Completed NCT02084849
30 Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease Completed NCT00598377 Tetracosactin
31 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study Completed NCT00571909
32 Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Completed NCT01039987
33 The Vienna RAP Pilot Study Completed NCT01632605 Sirolimus
34 High Water Intake to Slow Progression of Polycystic Kidney Disease Completed NCT00784030
35 Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease Completed NCT02776241
36 Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD Recruiting NCT02112136
37 Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial Recruiting NCT02948179
38 Efficacy of Tolvaptan on ADPKD Patients Recruiting NCT02729662 Tolvaptan
39 Canadian Medical Assessment of JINARC™ Outcomes Registry Recruiting NCT02925221
40 A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease Recruiting NCT03102632
41 PKD Clinical and Translational Core Study Recruiting NCT01873235
42 The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain Not yet recruiting NCT02746419
43 Repository Study of Autosomal Dominant Polycystic Kidney Disease Withdrawn NCT01988038

Search NIH Clinical Center for Polycystic Kidney Disease 1, Autosomal Dominant

Genetic Tests for Polycystic Kidney Disease 1, Autosomal Dominant

Genetic tests related to Polycystic Kidney Disease 1, Autosomal Dominant:

id Genetic test Affiliating Genes
1 Polycystic Kidney Disease 1, Autosomal Dominant 24 PKD1

Anatomical Context for Polycystic Kidney Disease 1, Autosomal Dominant

MalaCards organs/tissues related to Polycystic Kidney Disease 1, Autosomal Dominant:

39
Kidney, Liver

Publications for Polycystic Kidney Disease 1, Autosomal Dominant

Variations for Polycystic Kidney Disease 1, Autosomal Dominant

Expression for Polycystic Kidney Disease 1, Autosomal Dominant

Search GEO for disease gene expression data for Polycystic Kidney Disease 1, Autosomal Dominant.

Pathways for Polycystic Kidney Disease 1, Autosomal Dominant

GO Terms for Polycystic Kidney Disease 1, Autosomal Dominant

Sources for Polycystic Kidney Disease 1, Autosomal Dominant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....